Daewoong Pharmaceutical Holds 'NABOTA Symposium'
Daewoong Pharmaceutical Holds 'NABOTA Symposium'
  • Kim Min-jee
  • 승인 2018.11.20 12:05
  • 댓글 0
이 기사를 공유합니다

Daewoong Pharmaceutical held "NABOTA SYMPOSIUM" at Lotte Signature Hotel in Seoul on November 17 and 18. 

Daewoong Pharmaceutical announced on November 20 that it held "NABOTA SYMPOSIUM" at Lotte Signature Hotel in Seoul on November 17 and 18. 

The symposium commemorates the achievements of the NABOTA "DWP-450," which gained Canadian approval for the first time in Korea in August. More than 80 Korean plastic surgeons attended the symposium and shared Navota's clinical results.

"The Canadian sales permit is the first result of the recognition of Navota`s quality, safety and effectiveness by the advanced countries," said Park Sung-soo, head of the Nabota business. "With this symposium, I expect Navota to maintain its position as a premium toxin in both domestic and global markets."

Meanwhile, approval screening procedures of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for Daewoong Pharmaceutical are proceeding smoothly.

It is predicted that Nabota will be available in major advanced countries such as the U.S. in the first half of next year.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트